Tazarotene

Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when it is used. The possibility that a woman of childbearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50 mIU/mL for hCG should be obtained within 2 weeks prior toTazarotene therapy, which should begin during a normal menstrual period. Apply only to the affected areas. For external use only. Avoid contact with eyes, eyelids, and mouth. If contact with eyes occurs, rinse thoroughly with water. The safety of use of Tazarotene over more than 20% of body surface area has not been established in psoriasis or acne. Retinoids should not be used on eczematous skin, as they may cause severe irritation. Avoide sunlight. Use sunscreens (minimum SPF of 15) and protective clothing when using it. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using it. It should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.